Urological Care News
-
Treatment of Prostatitis - What Forms of Medicines Released?
Prostatitis is a disease characterized by the presence of inflammation and/or infection localized in the prostate gland. ...
-
Interim results of the Expander-1 Clinical Study
Medeon Biodesign, Inc. (TPEx: 6499), a Taiwan publicly traded medical device company, is pleased to announce positive interim results of the EXPANDER-1 Clinical Study for its flagship product the XFLO™ Expander System, an innovative, minimally invasive Benign Prostatic Hyperplasia (BPH) treatment solution. XFLO offers a reversible and office-based treatment option for patients who are ...
-
SafeHeal appoints medical device industry veteran Chris Richardson as Chief Executive Officer
PARIS, France/Tampa, FL – July, 11, 2022 – SafeHeal™, a leading innovator in the field of digestive surgery and developer of the Colovac device, announced today the appointment of Chris Richardson as Chief Executive Officer (CEO), who assumes responsibilities immediately. Richardson has over 30 years of experience in the medical device industry, and an extensive ...
By SafeHeal
-
Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference
The growing body of information regarding Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate cancer was highlighted in two presentations at the just concluded American Brachytherapy Society’s annual conference in Denver, Colorado. During the conference, the Prostate Snap Oral I scientific session included two abstracts that were presented by The Cesium Advisory ...
By Isoray Inc.
-
SafeHeal Announces Successful Launch of IDE Study for Colovac Endoluminal Bypass Sheath
Paris, France, & Guilford, CT – April 1, 2022 – SafeHeal™, a leading innovator in the field of digestive surgery, recently announced the first patient enrollment in its pivotal study of Colovac™, a groundbreaking endoluminal bypass sheath. Colovac is intended as an alternative to temporary diverting ostomy for patients undergoing colorectal resection. Up to 20 U.S. ...
By SafeHeal
-
Profound Medical to Participate in March Investor Conferences
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in two investor conferences in March. 42nd Annual Cowen Health Care Conference: Profound is scheduled ...
-
Profound Medical’s TULSA-PRO® Now Compatible with GE Healthcare’s 3T MRI Scanners
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today confirmed the TULSA-PRO® system’s new compatibility with GE Healthcare’s 3T Magnetic Resonance Imaging (“MRI”) scanners. ...
-
PROCEPT Announces 5-Year WATER Study Data Comparing Aquablation to TURP
REDWOOD CITY, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced positive five-year results from its 181 patient randomized WATER study comparing Aquablation therapy to TURP, the historical standard of care for treating BPH. WATER ...
-
Profound Medical to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, to be held virtually ...
-
SafeHeal closes €40 million financing co-led by Sofinnova Partners and Genesis MedTech to finance its Colovac device through a pivotal clinical trial in the United States
SafeHeal, a leading innovator in the field of digestive surgery and developer of the Colovac device, announced today a successful 40M€ financing, co-led by Sofinnova Partners and Genesis MedTech Group. Sofinnova Partners is a leading venture capital firm based in Paris, London and Milan and an historic shareholder in the company. Genesis MedTech is a medical device company headquartered in ...
By SafeHeal
-
Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the TULSA Procedure to Radical Prostatectomy
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that the first patients have been treated in the Level 1 ‘CAPTAIN’ trial. CAPTAIN (A Comparison of TULSA Procedure vs. Radical ...
-
« Back Northside Healthcare System in Atlanta Advances Surgical Robotics Program with Multi-System, Multi-Hospital Agreement for PROCEPT BioRobotics AquaBeam Systems
First and only image-guided, heat-free surgical robotic procedure aims to establish a new standard of care for patients with enlarged prostates REDWOOD CITY, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it now has five ...
-
Zenflow Launches Pivotal Clinical Trial of Minimally Invasive Spring Treatment for Enlarged Prostate Symptoms
Zenflow, Inc., a medical device company developing a minimally invasive treatment for enlarged prostate, or benign prostatic hyperplasia (BPH), has initiated the BREEZE™ pivotal clinical trial to evaluate its Spring System. The first procedure was successfully conducted by Michael D. Trotter, M.D., lead investigator at Midtown Urology Associates in Austin, Texas. Over 40 million men in the ...
-
Data presented at the American Urology Association annual conference
Data includes preliminary results from 39 patients at 4 centers across 3 countries – the temporary implant demonstrated the procedure was safe and provided immediate and sustained symptom relief. Prodeon Medical, Inc., a medical device company developing a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) caused by enlarged and obstructive benign prostatic ...
-
Promising Clinical Study Results of the Zenflow Spring System Featured at the AUA 2021 Meeting
Study results from the Spring System from Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), were featured at the American Urological Association 2021 annual meeting. The Spring System was designed with the patient experience in mind and relies on a small springlike coil to ...
-
Profound Medical to Participate in A.G.P.’s Virtual MedTech Summer Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in A.G.P.’s Virtual MedTech Summer Conference on Thursday, July 29, 2021. The event will consist of ...
-
Profound Medical and Akumin Enter into U.S. Multi-Center Commercial Agreement for TULSA-PRO
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the signing of a multi-site imaging center agreement for TULSA-PRO® with Akumin Inc. (NASDAQ/TSX:AKU) (“Akumin”), a leading ...
-
Profound Medical to Participate in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, ...
-
Profound Medical Signs Agreement with GE Healthcare to Expand Provider Access to TULSA-PRO
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that it has entered into a ...
-
Eakin Healthcare Group acquires Armstrong Medical continuing an ambitious growth strategy
Northern Ireland headquartered Eakin Healthcare Group has announced it is expanding into a new therapeutic area with the acquisition of Coleraine based Armstrong Medical, which specialises in respiratory care products. The deal represents a diversification for the Group which to date has specialised in ostomy and wound care products. The combined resources of the two indigenous NI healthcare ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you